Most pathogens enter the human body through mucosal surfaces—the moist linings of the respiratory tract, the gastrointestinal tract, and the urogenital tract. Yet, the vast majority of clinical vaccines are delivered via intramuscular injection. This spatial mismatch creates a profound biological disconnect known as the mucosal-systemic immunity gap.
To understand why this gap matters, we must look at how traditional vaccines distribute protection throughout the body, why they fail to prevent transmission, and how next-generation strategies are engineering a permanent "garrison" of immune cells directly at the borders of infection.
The Anatomy of the Gap
When a vaccine is injected into a muscle, it triggers a systemic immune response. As Jizong Jia explains in Exploring the standardized detection and sampling methods of human nasal SARS-CoV-2 RBD IgA, intramuscular vaccines primarily generate systemic Immunoglobulin G (IgG) antibodies that circulate in the bloodstream. These internal antibodies are highly effective at defending deep organs; they can clear viruses from the blood and prevent severe, life-threatening diseases like deep lung pneumonia.
However, systemic IgG cannot easily cross over to the outer surface of the mucosal linings. Kelly E. Seaton et al. note in their Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans that conventional vaccine development heavily prioritizes these blood-based responses, leaving a critical blind spot at the primary entry points of infection.
Without a frontline defense at the point of entry, pathogens can freely land on mucosal tissues, replicate, and shed into the environment. As a result, an individual can be perfectly protected against severe illness internally while still becoming infected and transmitting the pathogen to others. Romain Marlin et al. demonstrated this in Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques, showing that while systemic vaccines reduce overall viral load, they frequently fail to provide sterilizing immunity. For highly variable or aggressive pathogens, Norman L. Letvin et al. emphasize in Gene-based vaccination protects against mucosal infection by a heterologous highly pathogenic SIV isolate in rhesus monkeys that blocking initial viral acquisition at the mucosal surface remains the single most important hurdle to achieving true, population-wide protection.
The Local Garrison: Secretory IgA and Tissue-Resident Memory
Closing the immunity gap requires deploying two specialized types of immune sentinels directly to the mucosal border: secretory IgA (sIgA) and tissue-resident memory cells ($T_{RM}$ and $B_{RM}$).
Unlike the monomeric IgG found in blood, sIgA is a dimeric antibody specifically adapted to survive and function in the harsh, fluid-washed environments of our body's linings. Mengling Li et al. point out in Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development that intramuscular delivery almost entirely fails to stimulate sIgA production in the respiratory tract. When sIgA is present, it acts as a physical and chemical shield, neutralizing pathogens before they can even bind to host cells. The clinical value of this localized antibody shield is clear: Maya Aramaki et al. demonstrated in The Role of Salivary IgA Antibody against Periodontopathic Bacteria. that individuals who mount a strong, localized secretory immune response experience significantly less tissue damage and milder clinical symptoms when exposed to primary pathogens.
Complementing these antibodies are tissue-resident memory T cells ($T_{RM}$), which do not circulate in the blood but instead take up permanent residence within the mucosal tissue parenchyma. Traditional vaccines stimulate central memory T cells that live in distant lymph nodes. Catia Perciani et al. argue in Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women that these central memory cells respond too slowly to prevent initial infection; by the time they are alerted, multiply, and travel to the site of invasion, the pathogen has already breached the barrier.
In contrast, $T_{RM}$ cells act as an immediate alarm system. As detailed by Yangbao Lyu et al. in An Overview of Tissue-Resident Memory T Cells in the Intestine, the moment these resident cells detect a pathogen, they release localized inflammatory cytokines. These signals rapidly upregulate adhesion molecules on nearby blood vessels, effectively "pulling" circulating immune cells out of the bloodstream and into the tissue to crush the infection instantly. A parallel mechanism exists for humoral immunity: René Riedel et al. showed in Discrete populations of isotype-switched memory B lymphocytes are maintained in murine spleen and bone marrow that memory B cells also establish specialized, non-circulating tissue niches to maintain localized, long-term antibody memory.
Engineering Localized Priming and Recruitment
Because systemic injections cannot reliably seed these mucosal compartments, researchers are developing strategies to bypass the blood entirely through mucosal immune priming and site-specific recruitment signaling.
The most direct way to generate mucosal immunity is to deliver the vaccine directly to a mucosal surface, such as through nasal sprays or oral drops. This process targets mucosal-associated lymphoid tissues—like the nasal-associated lymphoid tissue (NALT)—to train immune cells right at the perimeter. Mengling Li et al. demonstrate in Development of universal influenza vaccines that intranasal priming successfully establishes both sIgA and $T_{RM}$ populations directly within the respiratory tract. Remarkably, because mucosal tissues are immunologically linked, priming one site can protect another. For example, Entao Li et al. showed in A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice that an intranasal vaccine could successfully induce specific sIgA in the small intestine, providing a needle-free pathway to gut immunity.
However, mucosal delivery faces steep physical hurdles: the body's natural clearance mechanisms, like mucus and beating cilia, are designed to rapidly sweep away foreign particles. To overcome this, researchers are engineering advanced biomaterials and adjuvants. Zhihan Zhang et al. highlight in Nanotechnology-driven advances in intranasal vaccine delivery systems against infectious diseases how nano-formulated delivery systems can penetrate the mucus barrier to induce robust Th17 and $T_{RM}$ responses. Furthermore, Jenny E. Hernandez‐Davies et al. demonstrated in Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants that combining mucosal delivery with potent synergistic adjuvants dramatically broadens the cross-reactivity of the resulting sIgA, allowing it to neutralize diverse viral variants at the point of entry.
[Systemic Injection] --------> High Blood IgG --------> Protects Internal Organs
|
v (Leaves Gap)
Vulnerable Mucosa
^
| (Bypasses Gap)
[Mucosal Priming] --------> Local sIgA + T_RM ------> Blocks Entry & Transmission
Crucially, simply dropping an antigen onto a mucosal surface is not always enough to convince memory cells to stay there permanently. To form a lasting garrison, circulating memory cells require specific local molecular cues to migrate into the tissue parenchyma and transform into resident cells.
Lisa E. Wagar et al. uncovered a vital mechanism behind this process in Intrinsic 4-1BB signals are indispensable for the establishment of an influenza-specific tissue-resident memory CD8 T-cell population in the lung. The authors discovered that signaling through the 4-1BB (CD137) receptor is absolutely required to anchor flu-specific CD8 T cells within the lung tissue. By delivering costimulatory ligands directly into the respiratory tract, they could artificially create the precise microenvironment needed to recruit passing memory cells and force them to take up permanent residence. Without these localized inflammatory or costimulatory signals—a principle also explored by Jiaqi Meng et al. regarding the localized recruitment of antigen-presenting cells in Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation—memory cells simply return to the bloodstream, leaving the border exposed.
By combining mucosal delivery routes with targeted molecular anchoring signals, modern vaccinology is learning to bridge the mucosal-systemic gap—transforming vaccines from internal safety nets into impenetrable frontline barriers that stop infections before they can start.
Key Foundational Work
P19-57 LB. Gene-based vaccination protects against mucosal infection by a heterologous highly pathogenic SIV isolate in rhesus monkeys (2009) — contributed 1 concept elements to this direction.
The Role of Salivary IgA Antibody against Periodontopathic Bacteria. (1996) — contributed 1 concept elements to this direction.